Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

Overview of attention for article published in Vascular Cell, September 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)

Mentioned by

blogs: 1 blog
twitter: 1 X user

patent: 5 patents

Citations

dimensions_citation: 372 Dimensions

Readers on

mendeley: 136 Mendeley

Summary Blogs X Patents Dimensions citations

So far, Dimensions has found 372 publications that cite this research output.

372

The most recent citing publications are shown below. View all 372 publications that cite this research output on Dimensions.

Lenvatinib‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis

Article in Oncology Letters (April 2024)

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma: a real-world study

Preprint in Research Square (April 2024)

Discovery of novel thiophene-3-carboxamide derivatives as potential VEGFR-2 inhibitors with anti-angiogenic properties

Article in Bioorganic Chemistry (April 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.